Veracyte is continuing to aggressively build its cancer diagnostics business with an agreement to acquire HalioDx for €147m ($180m) in cash and up to €113m ($138m) in stock, the companies announced on 1 June.
Veracyte Continues Cancer IVD Expansion By Acquiring HalioDx For $318M
The deal is Veracyte’s second major acquisition in cancer diagnostics in 2021 after agreeing to acquire Decipher Biosciences in March.
